Testing new drugs to help people with alcohol use disorder
Official title: Preclinical validation of mGlu2 PAMs in alcohol use disorder
Funded at Camino Pharma, LLC · NIH-10932992 · Data updated 2026-11-12
This study is looking at new medications that might help people with alcohol use disorder by improving how their brains work after drinking, and it aims to find better ways to support those trying to reduce their alcohol use and avoid relapse.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Camino Pharma, LLC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $994,906 |
| NIH project number | 5U43AA031388-02 |
| Project ID | NIH-10932992 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are struggling with alcohol use disorder.
✕Less likely to help
Patients who are not experiencing alcohol use disorder or are under 21 years old may not benefit from this research.
What this research studies
This research investigates the effectiveness of new compounds that target specific brain receptors to help reduce alcohol dependence and prevent relapse in individuals with alcohol use disorder (AUD). The study focuses on understanding how these compounds can normalize brain activity disrupted by chronic alcohol use. By examining the effects of these drugs on brain regions involved in alcohol-related behaviors, the research aims to develop better treatment options for those struggling with AUD. Participants may be involved in assessments that evaluate their response to these new therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective and better-tolerated treatments for individuals with alcohol use disorder.
How similar studies have gone: Previous research has shown promise in targeting glutamate receptors for treating substance use disorders, indicating potential for success in this approach.
Where this research is happening
-
Camino Pharma, LLC
San Diego, United States Active
Researchers
- Principal investigator: Gadient, Reto Andreas — Camino Pharma, LLC
- Study coordinator: Gadient, Reto Andreas
Related research
Other NIH-funded projects on the same topics.
-
Functional Connectivity-Guided TMS for Alcohol Use Disorder
A new approach uses targeted brain stimulation to help people with alcohol use disorder stay abstinent longer by focusing treatment on specific brain circuits.
-
Alcohol Use Disorder and Suicidal Behavior: Finding Why They Occur Together
A study using Swedish population data to understand why alcohol use disorder relates to suicidal thoughts and acts, with the goal of improving risk prediction and prevention.
-
Non-hallucinogenic psilocybin derivative for alcohol use disorder
A new, safer psilocybin-like compound is being studied to help people with alcohol use disorder.
-
Identifying brain proteins linked to PTSD and alcohol use disorder
Researchers are studying brain proteins that may contribute to PTSD and alcohol use disorder in US veterans to find new ways to help people who struggle with both conditions.
-
Mu and Kappa Opioid Balance in Alcohol Use Disorder
A study using brain imaging to understand how the brain’s opioid system changes during early sobriety in adults with alcohol use disorder.
-
Telehealth support to prevent suicide in people with alcohol use disorder in Tanzania
A telehealth counseling program is being adapted to help reduce suicide risk for people with alcohol use disorder in emergency departments in Tanzania.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.